GHDC two day climb from .004 to .03 Diabetes play ORGS up .05 at .65....Nice rebuilding from .50 followg runup to a buck in Oct...News today

 

 

 

 

From: Greenbackers

Sent: Wednesday, December 10, 2014 10:13 AM

Subject: ORGS up .05 at .65 Observe CYRN at 2.38 on significant deal

 

 

 

Focus:

 

 

ORGS jumped to .70 earlier.......If you look at the longer term chart, this stock as been steadily rebuilding off of .50 following a dramatic runup in Oct to a buck following patent news..

Orgenesis Inc. (ORGS)

-Other OTC

0.65  0.05(8.33%) 11:20AM EST

 

 

 

• Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in EuropeMarketwired(Mon, Nov 24)

• 
  How Orgenesis Hopes To Cure Type 1 DiabetesBenzinga(Mon, Nov 3)

• 
  Orgenesis Receives Patent for Potential Cure for Type 1 DiabetesMarketwired(Wed, Oct 15)

Note:  Greenbackers will be profiling ORGS to our  greater databases tomorrow pre mkt.

 

 

 

 

From: Greenbackers

Sent: Wednesday, December 10, 2014 7:30 AM

Subject: GHDC two day climb from .004 to .03 ORGS new rpt

 

 

Focus:

 

We mention GHDC yesterday, however overbought near term after further examinaton....None the less, expect volatility into morning as it finds topping out..

 

 

AXXE	Axxess Pharma and TapouT Fitness Announce Exclusive Alliance to Supply Gyms With TapouT Products at Marketwired Wed 8:00am

 

 

AZFL	Amazonas Florestal Ltd. Reorganizes Timber Subsidiary at Accesswire Tue 2:48pm
PROP	PROPELL TECHNOLOGIES GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale ofat EDGAR Online Tue 2:40pm
FNMA	Pershing Square takes on Zoetis, adds to Canadian Pacific in 3Q14 at Market Realist Tue 2:21pm

 

 

 

 

 

SRNA for holding .30....recall recent pickup on outside tout....Was 1.75 three mo ago..

 

 

 

Outside:

 

 

 

CEO Scott Carmer Interviewed on New Patent Award for Diabetes Cure

By Tobin Smith | December 9, 2014, 5:06pm GMT

Orgenesis (ORGS) is a public company committed to curing type 1 diabetes with a breakthrough technology that combines cellular therapy and regenerative medicine – "Cellular Transdifferentiation."

Professor Sarah Ferber and the research team at Orgenesis have successfully reprogrammedliver cells into fully functional Insulin Producing Cells (IPCs). They've had success curing diabetes in mice, and begin Phase 1 clinical trials in Type 1 diabetic patients in the next 12-15 months.

Unlike other diabetic treatments, the Orgenesis procedure is a cure for diabetics requiring insulin injections to regulate glucose in their blood stream.

Read the entire article here

http://asweetlife.org/feature/orgenesis-receives-new-patent-for-potential-t1d-cure/

 

 

 

 

 

Notable earnings before today's open: CMN, COST, FGP, FRAN, HOV, LAYN, LE, TITN, TOL, VRA

Notable earnings after today's close: AVNW, CASY, CENT, IRET, MW, PPHM, RH, SIGM, SURG, WTSL

 

 

 

007:

 

.

RIHT was up 38% yesterday to .24...

 

RIHT came up on top of my scanner hitting every algorithm to a T as the
perfect breakout chart formation.

Started digging into the company and found some interesting things:

• Revenue Positive
• RIHT was named as Top company in EContents 14th Annual Rankings
• RIHT has increased its number of participating ISP's by over 33pct.
• Featured in the Wall-street Journal
• Announced 282pct revenue increase in Q3 of 2014
• Q1 to Q3 2014 revenues have already exceeded all of 2013

Not to shabby for a 24 cent breakout play, no wonder RIHT is in a parabolic
uptrend lately.